Загрузка...

Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study

OBJECTIVE: We evaluated the effects of ursodeoxycholic acid (UDCA) on glucagon-like peptide-1 (GLP-1) secretion and glucose tolerance in patients with type 2 diabetes with chronic liver disease. RESEARCH DESIGN AND METHODS: Japanese patients with type 2 diabetes (glycated hemoglobin (HbA1c) levels ≥...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMJ Open Diabetes Res Care
Главные авторы: Shima, Kosuke Robert, Ota, Tsuguhito, Kato, Ken-ichiro, Takeshita, Yumie, Misu, Hirofumi, Kaneko, Shuichi, Takamura, Toshinari
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2018
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873545/
https://ncbi.nlm.nih.gov/pubmed/29607050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2017-000469
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!